November 29th 2023
Based on in vitro data, pacritinib led to a 4-fold higher potency for inhibition of the hepcidin regulator ACVR1 vs momelotinib among patients with cytopenic myelofibrosis and led to an increase in red blood cell transfusion independence.
November 21st 2023
November 20th 2023
40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes